跳至主要内容
临床试验/NCT01847729
NCT01847729已完成不适用

A Multicenter Study Assessing the Prevalence of Co-addictions in Subjects Receiving Maintenance Treatment for Opiate Dependence. Determination of Clinical and Pharmacological Profil.

Nantes University Hospital7 个研究点 分布在 1 个国家目标入组 263 人开始时间: 2013年7月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
263
试验地点
7
主要终点
Presence or absence of co-addictions (exept tobacco dependence)

研究概览

简要总结

The aim of this study is to determine the current prevalence of co-addictions, including problem/pathological gambling, in patients receiving Opiate Substitution Treatment (OST), and to then compare patients receiving OST with or without a co-addiction (excluding tobacco dependence) in order to determine their clinical profile.

In addition, an ancillary study to be carried out only among those patients receiving methadone, will aim to etablish whether a low plasma concentration of methadone, on the one hand, and an ultrarapid metabolizer genetic profile, on the other, are the characteristics most commonly associated with the presence of co-addictions. This will allow us to complete patient's pharmacological characterization.

详细描述

Non-interventionel study Total duration: 12 months (preparation, recruitment, analysis) Recruitment period: 6 months Duration of monitoring per patient: no monitoring

Main objective: to assess the current prevalence of addictive co-morbidities in opiate-dependent subjects receiving Opiate Substitution Treatment (OST) for at least 6 months.

Secondary objective: to compare patients being treated using OST who currently have a co-addiction (with the exception of tobacco dependence) with patients being treated with OST who do not currently have a co-addiction, based on pharmacological and clinical characteristics (for pharmacological characteristics: pharmacokinetic and pharmacogenetic analyses as part of an ancillary study into only those patients being treated with methadone).

Main judgment criterion: Presence or absence of co-addictions (except tobacco dependence), determined using assessment tools.

The secondary assessment criteria shall be: sociodemographic data, data about opiate dependence, data about other substance use disorders, data about gambling practice, psychopathological data (impulsivity, ADHD), pharmacokinetic data and pharmacogenetic data.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Under treatment unsing methadone or buprenorhine (+/- naloxone) or morphine as substitute, prescribed for opiate dependence,
  • OST begining at least 6 months previously,
  • Incarceration for less than a month in the event of monitoring in SMPR,
  • Good understanding of French, able to read and write.
  • General non-Inclusion Criteria:
  • Protected adults (guardianship, wardship)
  • Disorder of higher-order brains functions (severe cognitive disorders or confusion) or psychotic disorder (hallucinations, delusion) that may interfere with the study.
  • Non-Inclusion criteria for patients participating in the ancillary study:
  • Medical monitoring by a doctor from the Drug Addiction Network of the Nantes Area,
  • OST other than methadone
  • Adjustement to dosage in the 5 days prior to administering OST
  • Pregnant women
  • Absence of social security registration.

排除标准

  • 未提供

结局指标

主要结局

Presence or absence of co-addictions (exept tobacco dependence)

时间窗: 1 day

Questionnaire

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验

OPAL: "Opiates and PhArmacoLogy" | 临床试验